In this webinar, Jeremy M. Shefner, MD, PhD, Barrow Neurological Institute, reviews the large phase 2 study of CK107 that is now in progress across the US. He discusses the trial design, hopes for the drug, and answers questions from attendees.
CK107 is a fast skeletal muscle troponin activator that improves submaximal muscle function in animal models and normal human volunteers. It was designed to produce fewer negative effects than tirasemtiv, an agent with a similar mechanism of action that proved very difficult for ALS patients to tolerate.
